- Home
- IMUX vs KNDI Comparison
IMUX vs KNDI Comparison
Compare IMUX & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- KNDI
- Stock Information
- Founded
- IMUX 2016
- KNDI 2002
- Country
- IMUX United States
- KNDI China
- Employees
- IMUX N/A
- KNDI N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- KNDI Auto Manufacturing
- Sector
- IMUX Health Care
- KNDI Consumer Discretionary
- Exchange
- IMUX Nasdaq
- KNDI Nasdaq
- Market Cap
- IMUX 86.3M
- KNDI 91.2M
- IPO Year
- IMUX N/A
- KNDI N/A
- Fundamental
- Price
- IMUX $0.94
- KNDI $1.17
- Analyst Decision
- IMUX Strong Buy
- KNDI
- Analyst Count
- IMUX 6
- KNDI 0
- Target Price
- IMUX $12.67
- KNDI N/A
- AVG Volume (30 Days)
- IMUX 946.7K
- KNDI 115.2K
- Earning Date
- IMUX 02-20-2025
- KNDI 03-13-2025
- Dividend Yield
- IMUX N/A
- KNDI N/A
- EPS Growth
- IMUX N/A
- KNDI N/A
- EPS
- IMUX N/A
- KNDI N/A
- Revenue
- IMUX N/A
- KNDI $118,127,232.00
- Revenue This Year
- IMUX N/A
- KNDI N/A
- Revenue Next Year
- IMUX N/A
- KNDI N/A
- P/E Ratio
- IMUX N/A
- KNDI N/A
- Revenue Growth
- IMUX N/A
- KNDI N/A
- 52 Week Low
- IMUX $0.92
- KNDI $0.89
- 52 Week High
- IMUX $2.11
- KNDI $2.98
- Technical
- Relative Strength Index (RSI)
- IMUX 38.85
- KNDI 56.77
- Support Level
- IMUX $0.94
- KNDI $1.06
- Resistance Level
- IMUX $1.02
- KNDI $1.12
- Average True Range (ATR)
- IMUX 0.06
- KNDI 0.06
- MACD
- IMUX 0.00
- KNDI 0.00
- Stochastic Oscillator
- IMUX 13.58
- KNDI 53.85
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.